A Pill, Reimagined: How New Tech and U.S. Manufacturing Aid Cancer Care

IRVINE, CA – August 12, 2026 – On the surface, it’s a partnership to manufacture a pill. U.K.-based Cycle Pharmaceuticals has tapped California’s Forma Life Sciences to produce its new FDA-approved drug, CAVHANZA™, for the U.S. market. But digging into the details reveals a story that’s about much more than a simple supply agreement. It’s about deconstructing a life-saving therapy to its core components and rebuilding it to fit the realities of patient life, all while reinforcing a fragile national supply chain.

The collaboration centers on a treatment for a rare blood cancer, but its implications touch on some of the most critical systems shaping our future: patient-centric innovation, advanced manufacturing technology, and the strategic onshoring of critical infrastructure.

Simplifying a Complex Regimen

CAVHANZA is a new formulation of nilotinib, a well-established kinase inhibitor used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). For patients with this rare cancer, nilotinib is a crucial, often lifelong therapy that has turned a once-fatal disease into a manageable chronic condition. But “manageable” doesn’t always mean easy.

The conventional form of nilotinib comes with a strict and burdensome set of rules that can dominate a patient's day. It must be taken on an empty stomach, requiring a two-hour fast before the dose and another hour after. This rigid schedule can disrupt meals, work, and social life. More critically, the drug’s effectiveness plummets when taken with common acid-reducing medications like proton pump inhibitors (PPIs), which are used to treat heartburn and acid reflux. This is not a niche problem; one study found that nearly half of all Ph+ CML patients are prescribed PPIs at some point, creating a significant risk of drug-drug interactions that can compromise treatment.

This is the system Cycle Pharmaceuticals set out to redesign. CAVHANZA tackles these challenges head-on. Developed as an orally disintegrating tablet (ODT), it can be taken with or without water, a simple but meaningful benefit for patients who may have difficulty swallowing pills. More importantly, its formulation was engineered to be unaffected by food or stomach acid levels. Patients can take it without regard to mealtimes and, crucially, alongside PPIs or other acid reducers without the timing gymnastics required by its predecessor.

“Establishing U.S. manufacturing for CAVHANZA is an important step in our preparations to bring this differentiated treatment to patients,” said Catherine Wainwright, Chief Operations & Regulatory Officer at Cycle Pharmaceuticals. For patients, that differentiation translates directly into a less burdensome, more flexible daily routine, which in turn can lead to better adherence and better long-term outcomes.

The Technology Behind the Tablet

The secret to CAVHANZA’s patient-friendly features isn’t magic; it’s a sophisticated manufacturing process. Forma Life Sciences will produce the drug using a proprietary technology called ElectroNanoSpray™ (ENS). This isn't your standard pill-pressing operation.

ENS is a non-thermal particle engineering technology that uses an electric field to transform the drug into highly uniform, amorphous particles. Unlike conventional methods that rely on heat, which can degrade sensitive molecules, this ambient-temperature process preserves the drug’s integrity while radically increasing its surface area and solubility. This enhanced solubility is the key that unlocks the drug's new capabilities. It allows the nilotinib to be absorbed consistently by the body, regardless of whether the stomach is full, empty, or has its acidity reduced by a PPI.

The efficiency of this technology is remarkable. The ENS formulation allows CAVHANZA to achieve the same therapeutic effect as conventional nilotinib but with a 60% lower dose. This is a prime example of how process engineering can lead to a more elegant and potentially safer product.

“Our team is excited to bring its experience in complex oral drug products and commercial manufacturing to this important launch,” stated Armand Amin, President of Forma Life Sciences. The company, a specialized contract development and manufacturing organization (CDMO), represents a vital part of the modern pharmaceutical ecosystem, providing the specialized infrastructure and expertise that allows innovators like Cycle to bring complex products to market.

Onshoring a Critical Lifeline

The decision to manufacture CAVHANZA in Irvine, California, is also a deliberate strategic move that taps into a powerful national trend. The COVID-19 pandemic laid bare the vulnerabilities of a globalized pharmaceutical supply chain, where the U.S. is heavily reliant on overseas manufacturing for both finished drugs and their core ingredients. In response, a concerted push from both government and industry has emerged to bolster domestic production of critical medicines.

Initiatives from the FDA, such as the PreCheck pilot program, aim to streamline the regulatory process for new U.S.-based facilities, while broader policy directives seek to create a more resilient and secure national supply. The partnership between Cycle and Forma is a real-world manifestation of this strategy. By establishing a U.S. commercial supply from the outset, Cycle ensures a more reliable and secure source for American patients, insulating it from the geopolitical risks, shipping disruptions, and quality control challenges that can plague international supply lines.

For a rare disease drug, this is especially important. While the patient population is small, their need is critical and lifelong. Ensuring an uninterrupted supply isn't just a business goal; it's a public health imperative. This agreement shows a path forward, where specialized U.S.-based CDMOs like Forma become key partners in building a more robust domestic biopharma infrastructure, one critical drug at a time.